Resolution Chemicals Limited

Other

Derek McHattie

Alan Kenneth Greenwood

Parveen Bhatarah

Gary Hembra

Neil John Goodwin

Mark Philip Gamble

Christopher Murray

Alan Greenwood

Paul Christopher Marcus Hedger

Josef A Rechka

Mahmoud Aloui

Paul C M Hedger

Jerome Thomas Garfield Carr-Brion

Nicolas James Archer

A sterilizable particle-size reduction apparatus, component parts thereof and a method of sterilizing and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Particle size reduction apparatus, and use thereof

The present invention provides a process for handling &#x394;9-THC, which comprises preparing a solution of &#x394;9-THC in a solvent which exists as a gas at room temperature and atmospheric pressure. The invention also provides solutions of &#x394;9-THC in the solvent and solid preparations of &#x394;9-THC.

Delta 9&#x2014;tetrahydrocannabinol processing

Particle-size reduction apparatus, and use thereof

A process for the syntheses of 17&#x3b2;-hydroxy-7&#x3b1;-methyl-19-nor-17&#x3b1;-pregn-5(10)-ene-20-yne-3-one (tibolone, 11) and intermediates useful for the synthesis thereof. 

Process for the production of tibolone

A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilizing and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Particle-size reduction apparatus and use thereof

A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and a p-disubstituted benzene of formula (A) or 1,3,5-trimethylbenzene and obtaining cabergoline Form I from the solvate. Another aspect of the present invention provides a method for preparing cabergoline Form I comprising dissolving cabergoline in p-disubstituted benzene or 1,3,5-trimethylbenzene and recovering the cabergoline Form I polymorph, suitably by direct crystallization of Form I or by recovery of a solvate which can be converted to Form I. Another aspect of the present invention provides a novel cabergoline polymorph designated cabergoline Form Fand a method of preparing said polymorph by dissolving or forming a solvate of cabergoline in fluorobenzene and recovering cabergoline Form F.

Preparation of cabergoline

A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and 4-fluorotoluene or 1,3,5-trimethylbenzene and obtaining cabergoline Form I from the solvate. Another aspect of the present invention provides a method for preparing cabergoline Form I comprising dissolving cabergoline in 4-fluorotoluene or 1,3,5-trimethylbenzene and recovering the cabergoline Form 1 polymorph. Cabergoline Form I can then be obtained from the solution, suitably by direct crystallization of Form I or by recovery of a solvate which can be converted to Form I.

The present invention discloses a method for preparing cabergoline form I by combining cabergoline and a solvent comprising ethylbenzene to form a solvate and obtaining form I from the solvate. Also disclosed in a method for preparing cabergoline form I by combining cabergoline and a first solvent to form a solution and additionally including a second solvent to the solution, followed by crystallization to form cabergoline form I. Further disclosed is a solvate form of cabergoline comprising cabergoline and ethylbenzene and, optionally, n-heptane.

Preparation of citalopram comprises the steps of: (a) converting the compound of Formula (I) to a compound of Formula (II), wherein R in Formula (I) represents a Cto Calkylene group which may be substituted or unsubstituted, and Rin the compounds of Formula (II) represents a carboxylic acid group or a salt or an ester thereof; and (b) converting the compound of Formula (II) to form citalopram or a pharmaceutically acceptable salt thereof, or a direct conversion of the compound of Formula (I) to citalopram

Growing community of inventors

Stotfold, United Kingdom

Derek McHattie